Evidence map›Paper›PMID 25662856›Full record

ArticleVaccine2015

A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Rolando Pajon, Carolyn M Buckwalter, Kay O Johswich, Scott D Gray-Owen, Dan M Granoff

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rolando Pajon *Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA 94609 USA.
Carolyn M Buckwalter *Department of Molecular Genetics, University of Toronto, Toronto, Ontario Canada.
Kay O JohswichDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario Canada.
Scott D Gray-OwenDepartment of Molecular Genetics, University of Toronto, Toronto, Ontario Canada.
Dan M GranoffCenter for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA 94609 USA.
University of Toronto · CA

Funding

Novel vaccine strategies for prevention of N. meningitidis group B diseaseR01AI046464 · NIAID · OMVAX, INC. · PI MOE, GREGORY ROBERT · 2000 to 2024
$12.1M
An engineered meningococcal OMV vaccine for Africa against all capsular groupsR01AI082263 · NIAID · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI GRANOFF, DAN M. · 2010 to 2013
$2.1M
CONSTRUCTION OF THE VACCINE CENTERC06RR016226 · NCRR · CHILDREN'S HOSPITAL &RES CTR AT OAKLAND · PI LUCAS, ALEXANDER H. · 2002 to 2002
$2.0M
Canadian Institutes of Health Research MFE-135542Canadian Institutes of Health Research MOP-130273NCRR NIH HHS C06 RR016226NIAID NIH HHS AI046464NIAID NIH HHS AI082263NIAID NIH HHS R01 AI046464NIAID NIH HHS R01 AI082263
6 · The paper itself

Abstract

backgroundThe effect of protein-based meningococcal vaccines on prevention of nasopharyngeal colonization has been difficult to investigate experimentally because a reliable animal colonization model did not exist.

methodsHuman CEACAM1 transgenic mice, which can be colonized by meningococci, were immunized IP with one of two meningococcal native outer membrane vesicle (NOMV) vaccines prepared from mutants with attenuated endotoxin (lpxL1 knockout) and over-expressed sub-family B Factor H-binding proteins (FHbp). Animals were challenged intranasally two weeks after the third dose with wild-type strain H44/76, or were treated IP with anti-NOMV serum before and during the bacterial challenge.

resultsThe NOMV-1 vaccine, prepared from the serogroup B H44/76 mutant, elicited ∼40-fold higher serum bactericidal antibody titers against the wild-type H44/76 challenge strain than the NOMV-2 vaccine prepared from a heterologous serogroup W mutant strain with different PorA and FHbp amino acid sequence variants. Compared to aluminum hydroxide-immunized control mice, the efficacy for prevention of any H44/76 colonization was 93% (95% confidence interval, 52-99, P<0.0001) for the NOMV-1 vaccine, and 19% (-3-36, P=0.23) for NOMV-2. NOMV-2-vaccinated mice had a 5.6-fold decrease in geometric mean CFU of bacteria per animal in tracheal washes compared to control mice (P=0.007). The efficacy of passive administration of serum from NOMV-1-vaccinated mice to immunologically naïve mice against colonization was 44% (17-61; P=0.002).

conclusionsBoth NOMV vaccines protected against meningococcal colonization but there was greater protection by the NOMV-1 vaccine with antigens matched with the challenge strain. Meningococcal vaccines that target protein antigens have potential to decrease colonization.

Indexed as

AnimalsAntibodies, BacterialAntigens, BacterialAntigens, CDBacterial Outer Membrane ProteinsBacterial ProteinsCell Adhesion MoleculesEndotoxinsHumansImmunization, PassiveInjections, IntraperitonealMeningococcal InfectionsMeningococcal VaccinesMiceMice, TransgenicMutationAntibodies, BacterialAntigens, BacterialAntigens, CDBacterial Outer Membrane ProteinsBacterial ProteinsCD66 antigensCell Adhesion MoleculesEndotoxinsfactor H-binding protein, Neisseria meningitidisMeningococcal VaccinesColonization modelFactor H binding proteinFHbpNeisseria meningitidisOMVPorAVaccine

Identifiers

PMID25662856
PMCPMC4361389
OpenAlexW2025624184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.